Identified risk factors for developing hepatotoxicity with nevirapine are female gender, chronic hepatitis C/B virus coinfection, a CD4 count <250 cells/mm3 in women and <400/mm3 in men, and abnormal baseline transaminase levels.[8]. Here, CD4 is linked to chronic hepatitis C virus infection.